This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Praluent logo

Effect of Alirocumab on Mortality After  Acute Coronary Syndromes: An Analysis of  the ODYSSEY OUTCOMES Randomized  Clinical Trial. 
†With only nominal statistical significance by hierarchical testing (HR 0.85, 95% CI 0.73, 0.98)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES.


Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team

MAT-XU-2204597 (v3.0) Date of Preparation: October 2023